HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
Analysts and investors have turned their attention to a key regulatory meeting on peptides, a decision expected to trigger HIMS’ next phase of growth.
Stocktwits
More News
HIMS Stock Set To Test A Crucial Resistance – Is Retail Expecting A Breakout?
In April, the stock faced resistance near $30 and saw selling pressure in the following weeks.
Stocktwits
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Zacks
LLY Stock Heads To Record High – Here’s Why Retail’s Bullish On Latest GLP-1 Data
Eli Lilly reported promising data for Retatrutide and Foundayo at the American Diabetes Association (ADA) 86th Scientific Sessions over the weekend.
Stocktwits
TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 – Industry Leaders LLY, NVO To Remain Dominant
TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.
Stocktwits
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
Zacks
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.
Zacks
Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80%
As the patents for semaglutide near expiry in several countries this month, India has introduced a cost-effective alternative.
Stocktwits
Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial
Investors are closely watching the oral GLP-1 race as competition intensifies across the sector.
Stocktwits
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes
Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.